{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:29Z","timestamp":1767134909570,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006627","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000}}],"reference-count":404,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006627.pub2","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T14:38:38Z","timestamp":1256135918000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Ziprasidone versus other atypical antipsychotics for schizophrenia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Katja","family":"Komossa","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychosomatische und Medizin und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie der Universit\u00e4t Leipzig; Semmelweisstr. 10 04103 Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paranthaman Sethupathi","family":"Bhoopathi","sequence":"additional","affiliation":[{"name":"42 Meramanai Street Vettaikaranpudur, Pollachi (TK) Coimbatore(Dt) Tamilnadu India PIN 642129"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0001|cit1","first-page":"S125","article-title":"Ziprasidone vs risperidone in schizophrenia: efficacy and safety in an 8-week trial","volume":"5","author":"Addington","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial","volume":"65","author":"Addington","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006627.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.v67n0910","article-title":"The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone","volume":"67","author":"Phillips","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006627.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S0924-977X(02)80466-7","article-title":"Ziprasidone vs amisulpride for negative symptoms of schizophrenia","volume":"12","author":"Olie","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study","volume":"21","author":"Olie","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Sacchetti E Galluzzo A Valsecchi P Romeo F Gorini B Warrington L Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind 18-week trial Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada Toronto American Psychiatric Association 2006","DOI":"10.1016\/S0924-977X(06)70448-5"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006627.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/S0924-977X(06)70448-5","article-title":"Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial","volume":"16","author":"Sacchetti","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0011|cit11","unstructured":"Harvey PD Bowie C Loebel AD Long-term cognitive improvement: ziprasidone versus olanzapine: Proceeding of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA New York American Psychiatric Association 2004"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006627.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0924-977X(04)80360-2","article-title":"Cognitive improvement and neuropsychological normalization with ziprasidone or olanzapine: Results of a 6-month study","volume":"14","author":"Harvey","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00213-003-1652-2","article-title":"Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"172","author":"Harvey","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0014|cit14","unstructured":"Masand PS Loebel AD Analysis of remission in a six-month double-blind continuation study of ziprasidone versus olanzapine Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada Toronto American Psychiatric Association 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0015|cit15","unstructured":"Meyer J Nasrallah H Loebel A Parsons B Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia Proceedings of the Collegium Internationale Neuro-Psychopharmacologium 25th Biennial Congress; 2006 July 9-13; Chicago, Illinois Chicago Internationale Neuro-Psychopharmacologium 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0016|cit16","unstructured":"Meyer JM Loebel AD Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a six-week randomized study in patients with acute schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25;Toronto, Canada Toronto American Psychiatric Association 2006"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006627.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","article-title":"Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia","volume":"162","author":"Simpson","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0020|cit20","first-page":"4","article-title":"Comparison of olanzapine versus ziprasidone in acute schizophrenia","volume":"9","author":"Svestka","year":"2005","journal-title":"Psychiatrie Prague"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-6-8","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006627.pub2-BIB0022|cit22","first-page":"S403","article-title":"Side effects of atypical antipsychotics - prediction factor for compliance","volume":"16","author":"Baloescu","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0023|cit23","unstructured":"Hagger C Mitchell D Wise AL Schulz SC Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data Proceedings of the10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria Vienna Neuropsychopharmacology 1997"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0025|cit25","unstructured":"Harrison D Leaderer M Loebel A Murray S Ziprasidone vs. Olanzapine: change in coronary heart disease risk during a 6-week trial Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy Florence World Psychiatric Association 2004"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0026|cit26","unstructured":"Swanson JW Swartz MS Van Dorn RA Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada Toronto American Psychiatric Association 2006"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0027|cit27","first-page":"303","article-title":"A control study of ziprasidone vs clozapine in the treatment of refractory schizophrenia","volume":"11","author":"Tang","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006627.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/S0924-977X(06)70490-4","article-title":"Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia","volume":"16","author":"Tudor","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0029|cit29","first-page":"182","article-title":"Ziprasidone clinical trials conducted in Croatia","volume":"53","author":"Uzun","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0030|cit30","unstructured":"A1281039 double blind, double-dummy multicenter, parallel group comparison of the efficacy and the tolerability of ziprasidone vs. Clozapine in schizophrenic patients who are refractory and\/or intolerant to antipsychotic therapy ClinicalStudyResults.org 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0031|cit31","unstructured":"ACTRN12610000954022 An open randomised clinical trial involving haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone in first episode never-treated psychosis http:\/\/www.anzctr.org.au 2010"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Addington D Pantelis C Dineen M Loebel A Murray S Dunn J Ziprasidone vs risperidone in schizophrenia: 52 weeks\u2019 comparison Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004","DOI":"10.1016\/S0924-977X(03)91999-7"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/070674370905400108","article-title":"A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study","volume":"54","author":"Addington","year":"2009","journal-title":"Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.schres.2010.02.401","article-title":"Scoring algorithm for predicting long-term global functioning in patients with schizophrenia","volume":"117","author":"Agid","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0035|cit35","first-page":"418","article-title":"Effect of regression to the mean on drug-induced weight change","volume":"33","author":"Allison","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0036|cit36","unstructured":"Anon New Antipsychotic, new benefits? Current Drug Discovery 2002 11"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/S1516-44462011000100008","article-title":"Rapid tranquilization for agitated patients in emergency psychiatric rooms: A randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone","volume":"33","author":"Baldacara","year":"2011","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0038|cit38","unstructured":"Beuzen J-N Pans M Modell S Hagens P McQuade R Iwamato T Broad effectiveness trial with aripiprazole in Europe Eu-Beta Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0039|cit39","unstructured":"Beuzen J-N Schirr K Pans M Hagens P Kostic D Carson W Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ncl.2010.10.002","article-title":"Movement disorders induced by antipsychotic drugs: Implications of the catie schizophrenia trial","volume":"29","author":"Caroff","year":"2011","journal-title":"Neurologic Clinics"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0042|cit42","unstructured":"Addington D Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii 2011"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.09m05258gre","article-title":"Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia","volume":"72","author":"Addington","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.schres.2011.11.002","article-title":"Snp-based analysis of neuroactive ligand-receptor interaction pathways implicates pge2 as a novel mediator of antipsychotic treatment response: Data from the catie study","volume":"135","author":"Adkins","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00213-009-1627-z","article-title":"Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients","volume":"206","author":"Alkelai","year":"2009","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/10398560701689186","article-title":"Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists","volume":"15","author":"Bick","year":"2007","journal-title":"Australasian Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","article-title":"Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia","volume":"72","author":"Caroff","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.genhosppsych.2008.09.012","article-title":"The impact of obesity on health care costs among persons with schizophrenia","volume":"31","author":"Chwastiak","year":"2009","journal-title":"General Hospital Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.schres.2011.07.031","article-title":"Analysis of efficacy and side effects in catie demonstrates drug response subgroups and potential for personalized medicine","volume":"132","author":"Clark","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/ebmh.12.1.13","article-title":"Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia","volume":"12","author":"Covell","year":"2009","journal-title":"Evidence-Based Mental Health"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","article-title":"Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study","volume":"105","author":"Daumit","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"A119","DOI":"10.1016\/S1098-3015(10)70381-8","article-title":"Cost-effectiveness of aripiprazole for the management of schizophrenia in the United Kingdom","volume":"11","author":"Davies","year":"2008","journal-title":"Value in Health"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2005.10.004","article-title":"The CATIE schizophrenia effectiveness trial","volume":"80","author":"DeLisi","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006627.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.euroneuro.2007.02.006","article-title":"The long term--maximising potential for rehabilitation in patients with schizophrenia","volume":"17","author":"Fagiolini","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/JCP.0b013e31820597fa","article-title":"The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia","volume":"31","author":"Glick","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0269881106062765","article-title":"Selecting antipsychotics in schizophrenia: lessons from CATIE","volume":"20","author":"Haddad","year":"2006","journal-title":"Journal of Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archpsyc.64.6.631","article-title":"Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Heinrichs","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/ebmh.10.4.112","article-title":"Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia","volume":"10","author":"Heres","year":"2007","journal-title":"Evidence-Based Mental Health"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2011.01.022","article-title":"The association between weight change and symptom reduction in the catie schizophrenia trial","volume":"128","author":"Hermes","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270009343694","article-title":"Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking","volume":"1","author":"Jin","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2011.07.032","article-title":"Substance use and schizophrenia: Adverse correlates in the catie study sample","volume":"132","author":"Kerfoot","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0063|cit63","first-page":"14","article-title":"Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the catie study","volume":"7","author":"Levine","year":"2011","journal-title":"Value in Health"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2011.09.018","article-title":"Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the catie study","volume":"133","author":"Levine","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.schres.2012.01.014","article-title":"Treatment response trajectories and antipsychotic medications: Examination of up to18months of treatment in the catie chronic schizophrenia trial","volume":"137","author":"Levine","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1176\/appi.ajp.163.3.555-a","article-title":"Dr. Lieberman and colleagues reply","volume":"163","author":"Lieberman","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0067|cit67","first-page":"S32","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial","volume":"30","author":"Lieberman","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2753.2009.01189.x","article-title":"Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in canada: A cost-effectiveness analysis","volume":"16","author":"McIntyre","year":"2010","journal-title":"Journal of evaluation in clinical practice"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2008.04.023","article-title":"Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1","volume":"103","author":"Meyer","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2005.07.015","article-title":"The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome","volume":"80","author":"Meyer","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/schbul\/sbn067","article-title":"Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia","volume":"35","author":"Mohamed","year":"2009","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD006627.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1176\/appi.ajp.2008.07111713","article-title":"Relationship of cognition and psychopathology to functional impairment in schizophrenia","volume":"165","author":"Mohamed","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0076|cit76","unstructured":"NCT00014001 Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial) http:\/\/www.clinicaltrials.gov 2001"},{"issue":"7 Suppl 7","key":"10.1002\/14651858.CD006627.pub2-BIB0078|cit77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S1092852900026663","article-title":"Metabolic findings from the CATIE trial and their relation to tolerability","volume":"11","author":"Nasrallah","year":"2006","journal-title":"CNS Spectrums"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0077|cit78","first-page":"37","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in the CATIE schizophrenia trial","volume":"35","author":"Nasrallah","year":"2009","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2009.08.016","article-title":"The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial","volume":"115","author":"Penn","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2009.09.026","article-title":"Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial","volume":"116","author":"Perlick","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2012.01.015","article-title":"Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of catie data","volume":"137","author":"Rabinowitz","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11414-007-9101-3","article-title":"Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia","volume":"35","author":"Resnick","year":"2008","journal-title":"Journal of Behavioral Health Services and Research"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/14737167.7.2.103","article-title":"Second-generation antipsychotics: Reviewing the cost-effectiveness component of the catie trial","volume":"7","author":"Rosenheck","year":"2007","journal-title":"Expert Review of Pharmacoeconomics and Outcomes Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0086|cit84","first-page":"S32","article-title":"Cost-effectiveness of atypical antipsychotics in the CATIE schizophrenia trial","volume":"30","author":"Rosenheck","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0084|cit85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2008.09.031","article-title":"Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial","volume":"107","author":"Rosenheck","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0085|cit86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2009.06.002","article-title":"Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial","volume":"113","author":"Rosenheck","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.08.007","article-title":"Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial","volume":"80","author":"Stroup","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2011.04.012","article-title":"Longitudinal consent-related abilities among research participants with schizophrenia: Results from the catie study","volume":"130","author":"Stroup","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD006627.pub2-BIB0090|cit90","first-page":"707","article-title":"Pharmacogenetic studies in CATIE, a large randomized clinical trial for schizophrenia","volume":"141B","author":"Sullivan","year":"2006","journal-title":"American Journal of Medical Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1192\/bjp.bp.107.042630","article-title":"Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia","volume":"193","author":"Swanson","year":"2008","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/ps.2008.59.5.500","article-title":"What CATIE found: results from the schizophrenia trial","volume":"59","author":"Swartz","year":"2008","journal-title":"Psychiatric Services"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0094|cit94","first-page":"336","article-title":"A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial","volume":"153B","author":"Tsai","year":"2010","journal-title":"American Journal of Medical Genetics"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the catie study","volume":"51","author":"Wessels","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9 Suppl S","key":"10.1002\/14651858.CD006627.pub2-BIB0096|cit96","first-page":"250","article-title":"Genome-wide association study of smoking behavior among schizophrenics: Preliminary results","volume":"69","author":"Wiste","year":"2011","journal-title":"Biological Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.schres.2011.01.020","article-title":"Serological evidence of exposure to herpes simplex virus type 1 is associated with cognitive deficits in the catie schizophrenia sample","volume":"128","author":"Yolken","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0098|cit98","first-page":"135","article-title":"Genome-wide analysis of antipsychotic drug response in schizophrenia","volume":"50","author":"Zhang","year":"2011","journal-title":"Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0099|cit99","unstructured":"ChiCTR-TRC-10000934 Pharmacogenomic study of schizophrenia http:\/\/www.chictr.org\/ 2010"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0100|cit100","unstructured":"Dunn J Harrison DJ Cheli A Loebel A Murray S Ziprasidone vs olanzapine: change in CHD risk during a 6-week trial Proceedings of the 13th Association of European Psychiatrists Congress; 2005 Apr 2-6; Munich, Germany 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Eng SM Strom BL Faich G Reynolds RF D\u2019Agostino RB Ruskin J Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: the ziprasidone observational study of cardiac outcomes (ZODIAC) Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008","DOI":"10.1016\/j.schres.2007.12.377"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0104|cit102","unstructured":"Boter H The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens http:\/\/www.controlled-trials.com 2005"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0102|cit103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.08m04506yel","article-title":"Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST)","volume":"71","author":"Boter","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0103|cit104","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"\"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)\": correction","volume":"166","author":"Davidson","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.euroneuro.2010.02.001","article-title":"Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)","volume":"20","author":"Gaebel","year":"2010","journal-title":"European Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2009.09.022","article-title":"Correlates of cognitive impairment in first episode schizophrenia: The eufest study","volume":"115","author":"Galderisi","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0111|cit109","first-page":"A24","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"2","author":"Kahn","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0109|cit110","first-page":"S56","article-title":"EUFEST: A randomized pragmatic long-term trial in first episode schizophrenia","volume":"20","author":"Kahn","year":"2005","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0110|cit111","unstructured":"Kahn R Fleischhacker WW Karayal O Siu C Pappadopulos E EUFEST: the effects of first and second generation antipsychotics on metabolic and cardiovascular risk factors Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0113|cit112","unstructured":"Kahn RS Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0114|cit113","unstructured":"Kahn RS Effectiveness of second-generation antipsychotics in first episode schizophrenia: the EUFEST study Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"issue":"9618","key":"10.1002\/14651858.CD006627.pub2-BIB0112|cit114","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/JCP.0b013e3182199bcc","article-title":"Sexual dysfunction in first-episode schizophrenia patients results from european first episode schizophrenia trial","volume":"31","author":"Malik","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0116|cit116","unstructured":"NTR25 The european first episode schizophrenia trial (eufest): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens http:\/\/www.trialregister.nl\/trialreg\/index.asp 2005"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0117|cit117","first-page":"82","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder","volume":"12","author":"No","year":"2009","journal-title":"African Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/S0924-977X(10)70687-8","article-title":"Polish patients of the eufest study after 1 year antipsychotic treatment: Drug discontinuation and metabolic syndrome parameters","volume":"20","author":"Rabe-Jablonska","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0119|cit119","unstructured":"Rybakowski JK Vansteelandt K Szafranski T Thys E Jarema M Wolfgang Fleischhacker W Treatment of depression in first episode of schizophrenia: Results from eufest European Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.schres.2010.02.958","article-title":"Depressive symptoms in the first episode of schizophrenia - analysis of polish results of the eufest study","volume":"117","author":"Szafranski","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD006627.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4088\/JCP.10m06529","article-title":"Efficacy of antipsychotic drugs against hostility in the european first-episode schizophrenia trial (eufest)","volume":"72","author":"Volavka","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0122|cit122","first-page":"498","article-title":"Feasibility of quantifying activity energy expenditure and caloric intake by doubly-labeled water in treated patients with schizophrenia","volume":"33","author":"Fahnestock","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0123|cit123","unstructured":"Fleischhacker WW Safety and tolerability of first and second generation antipsychotics Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"issue":"18","key":"10.1002\/14651858.CD006627.pub2-BIB0124|cit124","first-page":"60","article-title":"A control study of olanzapine and ziprasidone in the treatment of adolescent schizophrenia","volume":"6","author":"Geng","year":"2008","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0125|cit125","first-page":"299","article-title":"The genetics and pharmacogenetics of neurocognition in patients with schizophrenia","volume":"33","author":"Goldstein","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0126|cit126","first-page":"61","article-title":"The clinical study of ziprasidone in treatment of first - episode schizophrenia","volume":"10","author":"Gong","year":"2008","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u533b\u836f\u6742\u5fd7"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0127|cit127","unstructured":"Gouzoulis-Mayfrank E Efficacy and tolerability of ziprasidone versus clozapine in the treatment of dually diagnosed (dd-) patients with schizophrenia and cannabis use disorder: a randomised study http:\/\/www.controlled-trials.com 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0128|cit128","unstructured":"Grootens K Veelen N Sitskoom M Verkes RJ Kahn R Effects of olanzapine and ziprasidone on cognitve outcome in recent-onset schizophrenia Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.euroneuro.2010.08.003","article-title":"Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia","volume":"20","author":"Grootens","year":"2010","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","article-title":"Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: Results of an 8-week double-blind randomized controlled trial","volume":"37","author":"Grootens","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0131|cit131","unstructured":"Harrison D Mackell J Leaderer M Ziprasidone versus olanzapine: changes in CHD risk during a 6-week trial Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0132|cit132","unstructured":"Harvey PD Cohen GM Loebel A Ziprasidone versus olanzapine in schizophrenia: 6-month cognitive data Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0133|cit133","first-page":"560","article-title":"Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double-blind comparative study","volume":"33","author":"Harvey","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006627.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/S0924-977X(07)70663-6","article-title":"Cognitive effects of ziprasidone and clozapine: results from an 18-week double-blind trial","volume":"17","author":"Harvey","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0135|cit135","unstructured":"Harvey PD Warrington L Loebel AD Romeo F Gorini B Galluzzo A Cognitive effects of ziprasidone and clozapine in treatment-resistant schizophrenia: results from an 18-week double-blind trial Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2007.11.014","article-title":"A randomized double-blind comparison of ziprasidone vs clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment","volume":"105","author":"Harvey","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0137|cit137","unstructured":"Houston JP Kaiser CJ Ahl J Berg PH Ahmed S Carlson C A comparison of the reduction of agitation in schizophrenic patients treated with olanzapine vs. ziprasidone in a 28-week double-blind study Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0138|cit138","first-page":"1389","article-title":"Observation of therapeutic effect of zipraside in the treatment of chronic schizophrenia","volume":"16","author":"Jiang","year":"2008","journal-title":"Chinese Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0139|cit139","first-page":"212","article-title":"The clincal study on ziprasidone and risperidone in the treatment of patients with first-onset schizophrenia","volume":"21","author":"Jiang","year":"2008","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0140|cit140","unstructured":"Johnsen E Kroken RA Wentzel-Larsen T Jorgensen HA A practical, randomized comparison of the effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-10-26","article-title":"Effectiveness of second-generation antipsychotics: A naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone","volume":"10","author":"Johnsen","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.schres.2010.02.675","article-title":"Anti-depressive effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone: A randomized, naturalistic study","volume":"117","author":"Johnsen","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0143|cit143","unstructured":"Johnsen E Jorgensen HA Kroken RA Loberg EM Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial European Psychiatry 22153730"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.schres.2010.02.227","article-title":"Primary and readjudication mortality results from zodiac, a large simple trial of ziprasidone vs. olanzapine in patients with schizophrenia","volume":"117","author":"Kane","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1301499","article-title":"Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial","volume":"33","author":"Keefe","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0146|cit146","unstructured":"Kinon BJ Lipkovich I Carlson C Dunayevich E Edwards SB Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-244X-11-145","article-title":"Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: A pragmatic, randomized trial","volume":"11","author":"Kjelby","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0030-1254089","article-title":"Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone","volume":"43","author":"Kuwilsky","year":"2010","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0149|cit149","first-page":"77","article-title":"Comparison of efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia","volume":"13","author":"Li","year":"2007","journal-title":"International Medicine and Health Guidance News [\u56fd\u9645\u533b\u836f\u536b\u751f\u5bfc\u62a5]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0150|cit150","first-page":"157","article-title":"Olanzapine and ziprasidone in the treatment of schizophrenia","volume":"20","author":"Li","year":"2007","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"17","key":"10.1002\/14651858.CD006627.pub2-BIB0151|cit151","first-page":"52","article-title":"Control study of ziprasidone and risperidone in the treatment of schizophrenia\u00a0","volume":"16","author":"Liang","year":"2007","journal-title":"China Pharmaceuticals [\u4e2d\u570b\u85e5\u696d]"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0152|cit152","first-page":"119","article-title":"Comparative study on ziprasidone and risperidone in the treatment of schizophrenia patients","volume":"31","author":"Liu","year":"2008","journal-title":"Journal of the Binzhou Medical College"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0153|cit153","first-page":"124","article-title":"A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms","volume":"16","author":"Liu","year":"2008","journal-title":"Chinese Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7]"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006627.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.1016\/S0924-977X(11)70811-2","article-title":"Crossover comparison of serum glycemia variability of intramuscular forms of antipsychotics: Aripiprazole, olanzapine and ziprasidone","volume":"21","author":"Loza","year":"2011","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0155|cit155","first-page":"336","article-title":"Comparative study of ziprasidone and risperidone in the treatment of schizophrenia","volume":"39","author":"Lu","year":"2007","journal-title":"\u9752\u5c9b\u533b\u836f\u536b\u751f"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0156|cit156","first-page":"335","article-title":"Comparing ziprasidone and olanzapine in treatment of schizophrenia","volume":"18","author":"Lu","year":"2008","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"4 Pt 3","key":"10.1002\/14651858.CD006627.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/15622970802269589","article-title":"Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial","volume":"10","author":"Lublin","year":"2009","journal-title":"World Journal of Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0158|cit158","first-page":"S202","article-title":"Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia","volume":"30","author":"Meyer","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0159|cit159","unstructured":"Meyer J Nasrallah H Loebel A Parsons B Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD006627.pub2-BIB0160|cit160","first-page":"159S","article-title":"Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia","volume":"59","author":"Meyer","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0161|cit161","unstructured":"Meyer J Loebel A Nasrallah H Parsons B Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: Results of a 6-week randomized study in patients with acute schizophrenia Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland Davos, SWITZERLAND Elsevier Science Bv 2006 93"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0162|cit162","unstructured":"Murray SR Addington DE Pantelis C Dineen M Romano SJ Ziprasidone versus risperidone in schizophrenia: a 52 weeks' comparison Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003 1"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0163|cit163","first-page":"226","article-title":"Comparative study on ziprasidone and risperidone in treating first episode schizophrenia","volume":"20","author":"Nai","year":"2008","journal-title":"Journal of the Henan Medical College for Staff and Workers"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0164|cit164","unstructured":"NCT00077727 A study of galantamine hbr as an adjunctive treatment to atypical antipsychotic medications in outpatients with schizophrenia and associated cognitive deficits http:\/\/www.clinicaltrials.gov 2004"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0165|cit165","unstructured":"NCT00145444 A multicenter, double-blind, randomized trial of ziprasidone (80 - 160 mg) versus olanzapine (10 - 20 mg) in patients with recent-onset schizophrenia, schizoaffective and schizophreniform disorder http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0166|cit166","unstructured":"NCT00148564 Energy homeostasis and metabolism in patients with schizophrenic disorders under treatment with atypical antipsychotics http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0167|cit167","unstructured":"NCT00159770 Tolerability, safety, and efficacy of ziprasidone (80 - 160 mg\/d) versus olanzapine (10 - 20 mg\/d), risperidone (4 - 8 mg\/d) or quetiapine (300 - 750 mg\/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders - a 12-week open-label, multicenter clinical trial http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0168|cit168","unstructured":"NCT00224315 Clozapine-augmentation with ziprasidone or risperidone, a randomized, prospective trial http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0169|cit169","unstructured":"NCT00225498 Neurocognitive effects of ziprasidone: relationship to working memory and dopamine blockade http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0170|cit170","unstructured":"NCT00239109 Ziprasidone versus olanzapine in the treatment of schizophrenia: a six months, double blind randomized, parallel group study http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0171|cit171","unstructured":"NCT00283179 Efficacy and safety of aripiprazole in the treatment of acutely relapsed patients with schizophrenia or schizoaffective disorder with risperidone as an active control http:\/\/www.clinicaltrials.gov 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0172|cit172","unstructured":"NCT00418171 An international, multicenter, large simple trial (LST) to compare the cardiovascular safety of ziprasidone and olanzapine http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0173|cit173","unstructured":"NCT00515723 Glucose and lipid metabolism on antipsychotic medication http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0174|cit174","unstructured":"NCT00634348 A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0175|cit175","unstructured":"NCT00645372 A study to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0176|cit176","unstructured":"NCT00645515 A study comparing the safety and efficacy of ziprasidone and risperidone for the treatment of chronic schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0177|cit177","unstructured":"NCT00649844 A study comparing the efficacy and tolerability of ziprasidone vs clozapine for the treatment of schizophrenia in patients who continue to have symptoms on or cannot tolerate other antipsychotic drugs http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0178|cit178","unstructured":"NCT00932529 Use, effects and side-effects of second-generation antipsychotics in a naturalistic setting http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0179|cit179","unstructured":"Newcomer JW Haupt DW Fahnestock PA Flavin KS Nicol GE Schweiger JA Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0180|cit180","unstructured":"Newcomer JW Haupt D Fahnestock P Flavin K Nicol G Schweiger J Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA San Diego, CA Oxford Univ Press 2009 361 2"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0181|cit181","first-page":"952","article-title":"A comparative study of ziprasidone and clozapine in treating schizophrenia","volume":"19","author":"Nie","year":"2007","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ps.62.10.pss6210_1138","article-title":"Predicting psychiatric hospital admission among adults with schizophrenia","volume":"62","author":"Olfson","year":"2011","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0183|cit183","unstructured":"Parsons B Zhang H Shu L Li H Gu N Wang G double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0184|cit184","unstructured":"Pfizer Effects of ziprasidone (80 - 160 mg\/d) versus olanzapine (10-20 mg\/d) on cognitive function in patients with schizophrenia or schizophrenic disorder previously treated with a typical neuroleptic drug (fluphenazine) - multicenter, randomized, double-blind (double-dummy), comparative study over 4 weeks with an open-label ziprasidone extension phase of up to one year http:\/\/www.clinicalstudyresults.org\/ 2005"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0185|cit185","unstructured":"Pfizer Down-titration schedules of amisulpride in patients suffering from schizophrenia or schizoaffective disorders when initiating therapy with ziprasidone: an open-label, three-months study http:\/\/www.clinicalstudyresults.org\/ 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0186|cit186","unstructured":"Pfizer A six week, multicenter, double-blind, double-dummy, parallel, comparative study to compare the efficacy, safety and tolerability of ziprasidone with risperidone in the treatment of Chinese subjects with acute exacerbation of schizophrenia ClinicalStudyResults.org 2007"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0187|cit187","first-page":"S287","article-title":"Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia","volume":"9","author":"Rappard","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006627.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1176\/appi.ajp.162.7.1391-a","article-title":"\"randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder\": comment","volume":"162","author":"Ross","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0189|cit189","unstructured":"Roychowdhury SM Sethuraman G Phillips GA Enerson M Berg PH Breier A Comparison of olanzapine to other atypical antipsychotics in preventing relapse in patients with schizophrenia Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0190|cit190","doi-asserted-by":"crossref","unstructured":"Sacchetti E Galluzzo A Valsecchi P Romeo F Gorini B Warrington L Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006","DOI":"10.1016\/S0924-977X(06)70448-5"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD006627.pub2-BIB0191|cit191","first-page":"158S","article-title":"Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial","volume":"59","author":"Sacchetti","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0192|cit192","first-page":"S274","article-title":"Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial","volume":"9","author":"Sacchetti","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0193|cit193","unstructured":"Sacchetti E Galluzzo A Romeo F Gorini B Warrington L Comparison of ziprasidone and clozapine in subgroups of patients with treatment-resistant schizophrenia Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0194|cit194","doi-asserted-by":"crossref","unstructured":"Sacchetti E Galluzzo A Romeo F Gorini B Warrington L Long-term efficacy of ziprasidone in treatment- resistant schizophrenia: results from a 1-year, open-label extension study Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007","DOI":"10.1016\/j.eurpsy.2007.01.538"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0195|cit195","first-page":"SME4","article-title":"Efficacy of ziprasidone in the treatment of resistant schizophrenia (organized by Pfizer)","volume":"8","author":"Sacchetti","year":"2009","journal-title":"World Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2009.02.017","article-title":"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study","volume":"110","author":"Sacchetti","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2009.05.002","article-title":"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study (DOI:10.1016\/j.schres.2009.02.017)","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.schres.2009.05.001","article-title":"\"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study\": corrigendum","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0199|cit199","unstructured":"Samochowiec J Tybura P Wysiecka JP Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0200|cit200","doi-asserted-by":"crossref","unstructured":"Schooler NR Buckley PF Mintz J Goff DC Kopelowicz A Lauriello J Proactive: Initial results of an rct comparing long-acting injectable risperidone to 2nd generation oral antipsychotics Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8;a, Waikoloa, Hawaii 2011 S104 S5","DOI":"10.1016\/S0920-9964(12)70019-1"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0201|cit201","doi-asserted-by":"crossref","unstructured":"Schooler NR Buckley PF Mintz J Goff DC Kopelowicz A Lauriello J Proactive: Initial results of an rct comparing long-acting injectable risperidone to 2nd generation oral antipsychotics Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii 2011","DOI":"10.1016\/S0920-9964(12)70019-1"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0202|cit202","first-page":"392","article-title":"Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia","volume":"17","author":"Shang","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0203|cit203","first-page":"69","article-title":"Influence of ziprasidone on quality on life of patients with schizophrenia","volume":"23","author":"Shang","year":"2008","journal-title":"Chinese Journal of Rehabilitation [\u4e2d\u570b\u5eb7\u5fa9]"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0204|cit204","first-page":"289","article-title":"Ziprasidone versus risperidone in the treatment of schizophrenia: cost-effectiveness analysis","volume":"8","author":"Shuai","year":"2008","journal-title":"Evaluation and Analysis of Drug-Use in Hospital of China"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1176\/appi.ajp.162.3.644","article-title":"Correction: \"randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder\"","volume":"162","author":"Simpson","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"149-63, xi","DOI":"10.1017\/CBO9780511663529.014","article-title":"Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: results of a double-blind, six-week study, with a six-month, double-blind, continuation phase","volume-title":"Progress in Neurotherapeutics and Neuropsychopharmacology","author":"Simpson","year":"2006"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0207|cit207","first-page":"101","article-title":"Ziprasidone versus risperidone: comparison of clinical efficacy and cardiac, extrapyramidal, and metabolic side effects in patients with acute exacerbation of schizophrenia and schizoaffective disorders","volume":"19","author":"Sonmez","year":"2009","journal-title":"Bulletin of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/01.jcp.0000096252.95165.a1","article-title":"The effect of antipsychotics on plasma lipids","volume":"23","author":"Sramek","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3928\/0048-5713-20000301-12","article-title":"Olanzapine for psychotic conditions in the elderly","volume":"30","author":"Street","year":"2000","journal-title":"Psychiatric Annals"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0210|cit210","first-page":"462","article-title":"Cardiac risk factors and schizophrenia: an analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone","volume":"33","author":"Strom","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0211|cit211","doi-asserted-by":"crossref","unstructured":"Strom BL Faich G Lombardo I Reynolds RF Eng SM Kane JM Cardiac risk factors and schizophrenia: an analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA 2007","DOI":"10.1016\/j.eurpsy.2007.01.352"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4088\/JCP.v69n0115","article-title":"The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics","volume":"69","author":"Strom","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006627.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.schres.2010.02.523","article-title":"The Ziprasidone Observational Study of Cardiac outcomes (ZODIAC): findings from a large simple trial of ziprasidone vs. Olanzapine in real-world use among 18154 patients with schizophrenia","volume":"117","author":"Strom","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2010.08040484","article-title":"Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (zodiac)","volume":"168","author":"Strom","year":"2011","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0215|cit215","first-page":"150","article-title":"Clinical comparative study of ziprasidone in the treatment of schizophrenia","volume":"20","author":"Sun","year":"2007","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0216|cit216","first-page":"4","article-title":"Comparison of olanzapine versus ziprasidone in acute schizophrenia","volume":"9","author":"Svestka","year":"2005","journal-title":"Psychiatrie Prague"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/ajp.2007.164.3.428","article-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study","volume":"164","author":"Swartz","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0218|cit218","first-page":"927","article-title":"A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents","volume":"6","author":"Tao","year":"2008","journal-title":"Journal of the Youjiang Medical College for Nationalities"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/ebmh.10.3.76","article-title":"Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia","volume":"10","author":"Taylor","year":"2007","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0220|cit220","unstructured":"Van Brunt DL Namjoshi M Xu W Berg PH Roychowdhury SM Cavazzoni P Clinical efficacy and quality of life in a clinical trial comparing olanzapine and ziprasidone Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"issue":"1-3","key":"10.1002\/14651858.CD006627.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.schres.2010.04.011","article-title":"Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia","volume":"120","author":"Veelen","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0222|cit222","unstructured":"Wang Y Guo H Liu Y Comparative study on the influence of ziprasidone and clozapine on quality of life in schizophrenic Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20-23; Shanghai 2007"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0223|cit223","first-page":"55","article-title":"Comparative study between ziprasidone and risperidone in treatment of schizophrenia","volume":"18","author":"Wang","year":"2008","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0224|cit224","first-page":"35","article-title":"A comparison study of ziprasidone and risperidone in treatment of schizophrenia","volume":"18","author":"Wang","year":"2008","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0225|cit225","first-page":"11","article-title":"Contrast study of treating schizophrenia by ziprasidone and risperidone","volume":"29","author":"Wang","year":"2008","journal-title":"Journal of Medical Forum [\u533b\u836f\u8bba\u575b\u6742\u5fd7]"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006627.pub2-BIB0226|cit226","first-page":"S243","article-title":"Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double-blind comparative study","volume":"31","author":"Warrington","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0227|cit227","first-page":"94","article-title":"A comparative study of ziprasidone and risperdone in the treatment of schizophrenia","volume":"21","author":"Wei","year":"2008","journal-title":"Sichuan Mental Health [\u56db\u5ddd\u7cbe\u795e\u536b\u751f]"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1185\/030079907X225448","article-title":"A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)","volume":"23","author":"Wolf","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0230|cit230","unstructured":"Woodruff P A phase IIIb, 12 week, muli-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone (40-80mg bid) versus olanzapine (5-20 mg od) on quality of life in the treatment of schizophrenia National Research Register 2003"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0231|cit231","first-page":"7","article-title":"Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version)","volume":"22","author":"Wu","year":"2012","journal-title":"East Asian Archives of Psychiatry"},{"issue":"23","key":"10.1002\/14651858.CD006627.pub2-BIB0232|cit232","first-page":"2760","article-title":"A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia","volume":"20","author":"Yang","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0233|cit233","first-page":"328","article-title":"A comparative study between ziprasidone and risperidone in the treatment of schizophrenia","volume":"22","author":"Yi","year":"2007","journal-title":"Journal of the North Sichuan Medical College"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0234|cit234","unstructured":"Yue W Zhang D Pharmacogenomic study of schizophrenia http:\/\/www.chictr.org\/ 2010"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0235|cit235","first-page":"1122","article-title":"Contrast study of treating schizophrenia by ziprasidone, clozapine and risperidone","volume":"20","author":"Zhang","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0236|cit236","first-page":"367","article-title":"A comparative study on the efficacy of ziprasidone and risperidone in the treatment of schizophrenia","volume":"21","author":"Zhang","year":"2008","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"17","key":"10.1002\/14651858.CD006627.pub2-BIB0237|cit237","first-page":"2002, 2004","article-title":"Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia","volume":"20","author":"Zhang","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/NDT.S16664","article-title":"double-blind comparison of ziprasidone and risperidone in the treatment of chinese patients with acute exacerbation of schizophrenia","volume":"7","author":"Zhang","year":"2011","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0239|cit239","first-page":"403","article-title":"A comparative study between ziprasidone and clozapine in the treatment of patients with schizophrenia","volume":"20","author":"Zhao","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0240|cit240","first-page":"16","article-title":"Ziprasidone and clozapine in treatment of schizophrenia","volume":"22","author":"Zhu","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/YIC.0b013e32816f7779","article-title":"Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study","volume":"22","author":"Zimbroff","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881108089593","article-title":"Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial","volume":"23","author":"Zink","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0243|cit243","first-page":"87","article-title":"A comparative study of ziprasidone and olanzapine in schizophrenia with predominantly negative symptoms","volume":"20","author":"Zou","year":"2008","journal-title":"Strait Pharmaceutical Journal"},{"issue":"7","key":"10.1002\/14651858.CD006627.pub2-BIB0244|cit244","first-page":"872","article-title":"30 cases of ziprasidone in combination with low-dose clozapine treatment of refractory schizophrenia\u00a0","volume":"28","author":"\u4efb\u5217","year":"2009","journal-title":"Herald of Medicine [\u533b\u836f\u5bfc\u62a5] [\u91ab\u85e5\u5c0e\u5831]"},{"issue":"20","key":"10.1002\/14651858.CD006627.pub2-BIB0245|cit245","first-page":"50","article-title":"Ziprasidone, and risperidone in the treatment of schizophrenia","volume":"9","author":"\u4f55\u6587\u521a","year":"2011","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"04","key":"10.1002\/14651858.CD006627.pub2-BIB0246|cit246","first-page":"267","article-title":"Three kinds of atypical antipsychotic drugs on the ECG of patients with schizophrenia","volume":"21","author":"\u5170\u5e86\u699c","year":"2011","journal-title":"\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"issue":"27","key":"10.1002\/14651858.CD006627.pub2-BIB0247|cit247","first-page":"124","article-title":"Ziprasidone, and risperidone in the treatment of schizophrenia","volume":"9","author":"\u5189\u660c\u534e","year":"2011","journal-title":"\u4e2d\u5916\u533b\u5b66\u7814\u7a76"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0248|cit248","first-page":"311","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"30","author":"\u5192\u96f7\u660e","year":"2010","journal-title":"\u5357\u901a\u5927\u5b66\u5b66\u62a5(\u533b\u5b66\u7248)"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0249|cit249","first-page":"106","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"20","author":"\u51af\u9f99\u559c","year":"2010","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"7","key":"10.1002\/14651858.CD006627.pub2-BIB0250|cit250","first-page":"48","article-title":"A controlled study of domestic ziprasidone and risperidone in the treatment of schizophrenia","volume":"13","author":"\u5218\u56fd\u96c4","year":"2007","journal-title":"International Medicine and Health Guidance News [\u56fd\u9645\u533b\u836f\u536b\u751f\u5bfc\u62a5]"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0251|cit251","first-page":"1302","article-title":"Quetiapine and ziprasidone on the impact of ECG qtc","volume":"17","author":"\u5218\u5fe0","year":"2009","journal-title":"Chinese Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7]"},{"issue":"23","key":"10.1002\/14651858.CD006627.pub2-BIB0252|cit252","first-page":"2778, 2780","article-title":"Ziprasidone and risperidone in the treatment of 60 female patients with schizophrenia\u00a0","volume":"20","author":"\u5218\u6653\u7ea2","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"22","key":"10.1002\/14651858.CD006627.pub2-BIB0253|cit253","first-page":"3636","article-title":"Ziprasidone and risperidone in the treatment of Schizophrenia","volume":"31","author":"\u5218\u6d2a\u79cb","year":"2010","journal-title":"Jilin Medical Journal"},{"issue":"21","key":"10.1002\/14651858.CD006627.pub2-BIB0254|cit254","first-page":"182","article-title":"Pharmacoeconomic analysis of clinical four antipsychotic treatment of schizophrenia","volume":"18","author":"\u5218\u743c\u534e","year":"2011","journal-title":"\u4e2d\u56fd\u5f53\u4ee3\u533b\u836f"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0255|cit255","first-page":"55","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia double-blind controlled study","volume":"22","author":"\u5355\u7f8e\u8273","year":"2009","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"15","key":"10.1002\/14651858.CD006627.pub2-BIB0256|cit256","first-page":"75","article-title":"Ziprasidone and quetiapine in the treatment of schizophrenia and security","volume":"20","author":"\u5362\u6bbf\u519b","year":"2011","journal-title":"\u4e2d\u56fd\u836f\u4e1a"},{"issue":"17","key":"10.1002\/14651858.CD006627.pub2-BIB0257|cit257","first-page":"1693","article-title":"The treatment of schizophrenia, the efficacy and safety of ziprasidone hydrochloride","volume":"40","author":"\u5362\u6bbf\u519b","year":"2011","journal-title":"\u91cd\u5e86\u533b\u5b66"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0258|cit258","first-page":"47","article-title":"Control study observed 50 cases of the treatment of youth schizophrenia\u00a0","volume":"16","author":"\u5434\u8fdc\u82b3","year":"2008","journal-title":"\u5175\u56e2\u533b\u5b66"},{"issue":"18","key":"10.1002\/14651858.CD006627.pub2-BIB0259|cit259","first-page":"2142","article-title":"Ziprasidone and clozapine in the treatment of the negative symptoms of schizophrenia research\u00a0","volume":"18","author":"\u5468\u4e91","year":"2009","journal-title":"Modern Research of Integrated Chinese and Western Medicine [\u73b0\u4ee3\u4e2d\u897f\u533b\u7ed3\u5408\u6742\u5fd7]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0260|cit260","first-page":"190","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia\u00a0","volume":"19","author":"\u5468\u6d77\u6653","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0261|cit261","first-page":"17","article-title":"Ziprasidone and aripiprazole the efficacy and safety of the treatment of schizophrenia","volume":"11","author":"\u55bb\u5fd7\u654f","year":"2010","journal-title":"\u5b9e\u7528\u4e34\u5e8a\u533b\u5b66"},{"issue":"19","key":"10.1002\/14651858.CD006627.pub2-BIB0262|cit262","first-page":"2109","article-title":"Ziprasidone for schizophrenia and the effect of quality of life","volume":"25","author":"\u5b59\u4ed8\u6839","year":"2009","journal-title":"Occupation and Health [\u804c\u4e1a\u4e0e\u5065\u5eb7]"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0263|cit263","first-page":"360","article-title":"Efficacy and adverse reactions of ziprasidone in 30 female patients with schizophrenia","volume":"28","author":"\u5b59\u4ed8\u6839","year":"2009","journal-title":"Chinese Journal of New Drugs and Clinical Remedies [\u4e2d\u56fd\u65b0\u836f\u4e0e\u4e34\u5e8a\u6742\u5fd7]"},{"issue":"04","key":"10.1002\/14651858.CD006627.pub2-BIB0264|cit264","first-page":"16","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia analysis","volume":"34","author":"\u5b59\u5e73","year":"2011","journal-title":"\u9ed1\u9f99\u6c5f\u533b\u836f\u79d1\u5b66"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0265|cit265","first-page":"1141","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"20","author":"\u5b59\u6bc5","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0266|cit266","first-page":"350","article-title":"Ziprasidone given with Risperdal in the treatment of schizophrenia","volume":"21","author":"\u5b59\u7231\u6c11","year":"2010","journal-title":"Aerospace Medicine"},{"issue":"21","key":"10.1002\/14651858.CD006627.pub2-BIB0267|cit267","first-page":"64","article-title":"30 cases of ziprasidone on the quality of life of patients with schizophrenia","volume":"18","author":"\u5b63\u6797\u5f71","year":"2009","journal-title":"China Pharmaceuticals [\u4e2d\u570b\u85e5\u696d]"},{"issue":"31","key":"10.1002\/14651858.CD006627.pub2-BIB0268|cit268","first-page":"5556","article-title":"Ziprasidone and risperidone in the treatment of women with schizophrenia","volume":"31","author":"\u5b8b\u65b0\u8679","year":"2010","journal-title":"Jilin Medical Journal"},{"issue":"17","key":"10.1002\/14651858.CD006627.pub2-BIB0269|cit269","first-page":"10","article-title":"Ziprasidone and clozapine in the treatment of schizophrenia control study","volume":"3","author":"\u5bc7\u6842\u654f","year":"2009","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u836f\u7269\u5e94\u7528"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0270|cit270","first-page":"1505","article-title":"Risperidone and ziprasidone on cognitive function in patients with schizophrenia\u00a0","volume":"30","author":"\u5c48\u5efa\u65b0","year":"2008","journal-title":"Hebei Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0271|cit271","first-page":"7","article-title":"Ziprasidone and risperidone on prolactin in patients with schizophrenia and body mass, blood glucose, blood lipid","volume":"23","author":"\u5d14\u5f00\u8273","year":"2010","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0272|cit272","first-page":"61","article-title":"Domestic ziprasidone treatment of schizophrenia clinical observation","volume":"45","author":"\u5d14\u96bd","year":"2007","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u533b\u751f"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0273|cit273","first-page":"119","article-title":"Ziprasidone and clozapine in the treatment of schizophrenia","volume":"20","author":"\u5e9e\u826f\u4fca","year":"2010","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0274|cit274","first-page":"568","article-title":"Ziprasidone and clozapine in the treatment of schizophrenia with negative symptoms associated control study","volume":"22","author":"\u5f20\u5c0f\u667a","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"22","key":"10.1002\/14651858.CD006627.pub2-BIB0275|cit275","first-page":"2840","article-title":"Change-control study of ziprasidone and risperidone-induced weight and metabolic indicators","volume":"22","author":"\u5f20\u5cf0","year":"2010","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"13","key":"10.1002\/14651858.CD006627.pub2-BIB0276|cit276","first-page":"31","article-title":"Control study of ziprasidone and risperdone in the treatment of schizophrenia","volume":"12","author":"\u5f20\u660e\u677e","year":"2009","journal-title":"\u4e2d\u56fd\u5b9e\u7528\u795e\u7ecf\u75be\u75c5\u6742\u5fd7"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0277|cit277","first-page":"44","article-title":"Ziprasidone treatment of schizophrenia with depressive symptoms were observed","volume":"20","author":"\u5f20\u7396\u9f99","year":"2010","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0278|cit278","first-page":"532","article-title":"Ziprasidone and clozapine in the treatment of refractory schizophrenia","volume":"22","author":"\u5f20\u8273\u7426","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0279|cit279","first-page":"320","article-title":"Ziprasidone treatment of simple type schizophrenia","volume":"19","author":"\u5f20\u9999\u829d","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"22","key":"10.1002\/14651858.CD006627.pub2-BIB0280|cit280","first-page":"2076","article-title":"Efficacy and safety of ziprasidone treatment of schizophrenia with acute exacerbation","volume":"19","author":"\u5f20\u9e3f\u71d5","year":"2010","journal-title":"\u4e2d\u56fd\u65b0\u836f\u6742\u5fd7"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0281|cit281","first-page":"125","article-title":"Ziprasidone clinical study of treatment of schizophrenia","volume":"21","author":"\u5f6d\u4eae","year":"2010","journal-title":"\u4e2d\u5916\u533b\u7597"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0282|cit282","first-page":"168","article-title":"Comparative analysis of ziprasidone risperidone in the treatment of female schizophrenia\u00a0","volume":"22","author":"\u5f6d\u6c5d\u6625","year":"2009","journal-title":"Sichuan Mental Health [\u56db\u5ddd\u7cbe\u795e\u536b\u751f]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0283|cit283","first-page":"98","article-title":"Ziprasidone and olanzapine schizophrenia","volume":"8","author":"\u5f90\u56fd\u6d2a","year":"2010","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0284|cit284","first-page":"556","article-title":"A randomized, double blind, double dummy parallel controlled study schizophrenia treated with ziprasidone tablets and risperidone orally disintegrating tablets","volume":"15","author":"\u5f90\u5a1f","year":"2009","journal-title":"Chinese Journal of Rehabilitation Theory and Practice [\u4e2d\u56fd\u5eb7\u590d\u7406\u8bba\u4e0e\u5b9e\u8df5]"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0285|cit285","first-page":"87","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"23","author":"\u5f90\u677e","year":"2010","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"03","key":"10.1002\/14651858.CD006627.pub2-BIB0286|cit286","first-page":"174","article-title":"Risperidone sustained release tablets and the ziprasidone treatment of schizophrenia","volume":"21","author":"\u5f90\u8389\u840d","year":"2011","journal-title":"\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"issue":"15","key":"10.1002\/14651858.CD006627.pub2-BIB0287|cit287","first-page":"1942","article-title":"Ziprasidone and quetiapine in the treatment of women with schizophrenia","volume":"22","author":"\u65b9\u4f20\u8363","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"06","key":"10.1002\/14651858.CD006627.pub2-BIB0288|cit288","first-page":"330","article-title":"Aripiprazole and ziprasidone in patients with schizophrenia glucose, lipids","volume":"7","author":"\u6613\u5cf0","year":"2010","journal-title":"\u4e2d\u56fd\u836f\u7269\u5e94\u7528\u4e0e\u76d1\u6d4b"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0289|cit289","first-page":"2196","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"8","author":"\u6731\u5fd7\u9ad8","year":"2010","journal-title":"Medical Information"},{"issue":"22","key":"10.1002\/14651858.CD006627.pub2-BIB0290|cit290","first-page":"2841","article-title":"Ziprasidone and clozapine in the treatment of schizophrenia","volume":"22","author":"\u674e\u4ed5\u519b","year":"2010","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"15","key":"10.1002\/14651858.CD006627.pub2-BIB0291|cit291","first-page":"1924","article-title":"Ziprasidone and clozapine in patients with first-episode schizophrenia Comparison of the effects of ECG","volume":"22","author":"\u674e\u4f5c\u73cd","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0292|cit292","first-page":"440","article-title":"Ziprasidone and risperidone in the treatment of senile schizophrenia\u00a0","volume":"21","author":"\u674e\u542f\u658c","year":"2008","journal-title":"Acta Medicinae Sinica [\u534e\u590f\u533b\u5b66]"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0293|cit293","first-page":"1358","article-title":"Ziprasidone and olanzapine clinical control study of schizophrenia","volume":"22","author":"\u674e\u56fd\u80dc","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"06","key":"10.1002\/14651858.CD006627.pub2-BIB0294|cit294","first-page":"404","article-title":"Ziprasidone treatment of schizophrenia, randomized, double-blind controlled study","volume":"20","author":"\u674e\u57f9\u8f69","year":"2010","journal-title":"\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"issue":"07","key":"10.1002\/14651858.CD006627.pub2-BIB0295|cit295","first-page":"98","article-title":"Ziprasidone merged observation and care of small doses of clozapine treatment of refractory schizophrenia","volume":"9","author":"\u674e\u6625\u82b1","year":"2011","journal-title":"\u6c42\u533b\u95ee\u836f(\u4e0b\u534a\u6708)"},{"issue":"17","key":"10.1002\/14651858.CD006627.pub2-BIB0296|cit296","first-page":"2020","article-title":"Ziprasidone and risperidone in the treatment of chronic schizophrenia\u00a0","volume":"20","author":"\u674e\u6811\u654f","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"24","key":"10.1002\/14651858.CD006627.pub2-BIB0297|cit297","first-page":"1","article-title":"Three kinds of antipsychotic drugs on glucose metabolism in patients with schizophrenia","volume":"15","author":"\u674e\u6881","year":"2009","journal-title":"\u5f53\u4ee3\u533b\u5b66"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0298|cit298","first-page":"151","article-title":"Ziprasidone and clozapine in the treatment of schizophrenia","volume":"44","author":"\u674e\u8f76\u7fa4","year":"2009","journal-title":"Jiangxi Medical Journal [\u6c5f\u897f\u533b\u836f]"},{"issue":"25","key":"10.1002\/14651858.CD006627.pub2-BIB0299|cit299","first-page":"242","article-title":"Controlled study of aripiprazole and ziprasidone treatment of schizophrenia","volume":"9","author":"\u6768\u660e\u534e","year":"2011","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0300|cit300","first-page":"1156","article-title":"Ziprasidone and risperidone in the treatment of female control study of schizophrenia","volume":"17","author":"\u6768\u8001\u864e","year":"2009","journal-title":"Chinese Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7]"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0301|cit301","first-page":"1197","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia control study\u00a0","volume":"27","author":"\u6768\u80dc\u826f","year":"2008","journal-title":"Herald of Medicine [\u533b\u836f\u5bfc\u62a5] [\u91ab\u85e5\u5c0e\u5831]"},{"issue":"18","key":"10.1002\/14651858.CD006627.pub2-BIB0302|cit302","first-page":"2816","article-title":"Association study of four kinds of antipsychotics and glucose metabolism in patients with schizophrenia and glycosylated hemoglobin","volume":"20","author":"\u6768\u8bda","year":"2010","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u533b\u5b66\u6742\u5fd7"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0303|cit303","first-page":"409","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia control study\u00a0","volume":"20","author":"\u6768\u987a\u624d","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0304|cit304","first-page":"97","article-title":"Comparison of health economics ziprasidone, clozapine treatment","volume":"19","author":"\u6797\u5353\u6bc5","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"14","key":"10.1002\/14651858.CD006627.pub2-BIB0305|cit305","first-page":"1708","article-title":"Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia","volume":"23","author":"\u6797\u654f","year":"2011","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"6","key":"10.1002\/14651858.CD006627.pub2-BIB0306|cit306","first-page":"771","article-title":"Ziprasidone and clozapine in the treatment of female schizophrenia","volume":"16","author":"\u6bb5\u6b66\u521a","year":"2010","journal-title":"Journal of the Hainan Medical College"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0307|cit307","first-page":"156","article-title":"Ziprasidone social function in patients with schizophrenia and quality of life","volume":"25","author":"\u6bb5\u6b66\u94a2","year":"2010","journal-title":"Chinese Journal of Rehabilitation [\u4e2d\u570b\u5eb7\u5fa9]"},{"issue":"23","key":"10.1002\/14651858.CD006627.pub2-BIB0308|cit308","first-page":"3042","article-title":"80 controls were observed ziprasidone and risperidone in the treatment of schizophrenia\u00a0","volume":"22","author":"\u6bb7\u6708\u73cd","year":"2010","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"04","key":"10.1002\/14651858.CD006627.pub2-BIB0309|cit309","first-page":"44","article-title":"Controlled study of ziprasidone and risperidone in the treatment of women with schizophrenia","volume":"8","author":"\u6e29\u5360\u7ea2","year":"2011","journal-title":"\u5317\u65b9\u836f\u5b66"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0310|cit310","first-page":"348","article-title":"Controlled clinical studies of ziprasidone and clozapine in the treatment of schizophrenia\u00a0","volume":"30","author":"\u6f58\u5929\u4f1f","year":"2008","journal-title":"Guangxi Medical Journal"},{"issue":"13","key":"10.1002\/14651858.CD006627.pub2-BIB0311|cit311","first-page":"22","article-title":"Ziprasidone impact on the quality of life in patients with schizophrenia\u00a0","volume":"6","author":"\u6f58\u6587\u71d5","year":"2008","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"01","key":"10.1002\/14651858.CD006627.pub2-BIB0312|cit312","first-page":"9","article-title":"Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia","volume":"8","author":"\u718a\u8f89","year":"2011","journal-title":"\u68c0\u9a8c\u533b\u5b66\u4e0e\u4e34\u5e8a"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0313|cit313","first-page":"1","article-title":"Comparison of the effects of ziprasidone and clozapine, risperidone on lipid metabolism in patients with schizophrenia","volume":"14","author":"\u738b\u4f53\u5bbe","year":"2011","journal-title":"\u4e2d\u56fd\u5b9e\u7528\u795e\u7ecf\u75be\u75c5\u6742\u5fd7"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0314|cit314","first-page":"206","article-title":"Ziprasidone treatment of schizophrenia with predominantly negative symptoms\u00a0","volume":"18","author":"\u738b\u5929\u9f99","year":"2008","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"23","key":"10.1002\/14651858.CD006627.pub2-BIB0315|cit315","first-page":"156","article-title":"Efficacy of ziprasidone treatment of schizophrenia and quality of life","volume":"4","author":"\u738b\u5b66\u519b","year":"2009","journal-title":"\u4e2d\u56fd\u5b9e\u7528\u533b\u836f"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0316|cit316","first-page":"26","article-title":"Ziprasidone and risperidone in the treatment of women with schizophrenia","volume":"8","author":"\u738b\u65b9\u56fd","year":"2010","journal-title":"\u793e\u533a\u533b\u5b66\u6742\u5fd7"},{"issue":"36","key":"10.1002\/14651858.CD006627.pub2-BIB0317|cit317","first-page":"5","article-title":"Ziprasidone and clozapine on cognitive function in patients with schizophrenia","volume":"5","author":"\u738b\u6c38\u5b66","year":"2010","journal-title":"\u4e2d\u56fd\u5b9e\u7528\u533b\u836f"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0318|cit318","first-page":"2570","article-title":"Aripiprazole and ziprasidone, the prevalence of metabolic syndrome in patients with schizophrenia","volume":"6","author":"\u738b\u79c0\u82b3","year":"2011","journal-title":"\u533b\u5b66\u4fe1\u606f(\u4e2d\u65ec\u520a)"},{"issue":"23","key":"10.1002\/14651858.CD006627.pub2-BIB0319|cit319","first-page":"2993","article-title":"Effective control study of ziprasidone and risperidone in first episode schizophrenia","volume":"22","author":"\u738b\u91d1\u5802","year":"2010","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0320|cit320","first-page":"199","article-title":"Ziprasidone and aripiprazole in the treatment of schizophrenia","volume":"41","author":"\u767d\u5251\u6587","year":"2009","journal-title":"\u9752\u5c9b\u533b\u836f\u536b\u751f"},{"issue":"17","key":"10.1002\/14651858.CD006627.pub2-BIB0321|cit321","first-page":"8","article-title":"Three kinds of atypical antipsychotic drugs on lipid metabolism in patients with schizophrenia","volume":"8","author":"\u767d\u9526\u6ce2","year":"2010","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0322|cit322","first-page":"573","article-title":"Ziprasidone and risperidone in the treatment of Schizophrenia","volume":"22","author":"\u76ae\u73a5\u73a5","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"21","key":"10.1002\/14651858.CD006627.pub2-BIB0323|cit323","first-page":"2714","article-title":"Ziprasidone and clozapine on ECG","volume":"22","author":"\u79e6\u6377","year":"2010","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0324|cit324","first-page":"106","article-title":"Ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms\u00a0","volume":"23","author":"\u7a0b\u5e73","year":"2009","journal-title":"Journal of the Xianning Medical College [\u65b0\u4e61\u533b\u5b66\u9662\u5b66\u62a5]"},{"issue":"14","key":"10.1002\/14651858.CD006627.pub2-BIB0325|cit325","first-page":"157","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia in the clinical control study","volume":"3","author":"\u7a0b\u71d5","year":"2009","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u836f\u7269\u5e94\u7528"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0326|cit326","first-page":"843","article-title":"Ziprasidone and quetiapine in the treatment of senile schizophrenia","volume":"11","author":"\u7ba1\u92ae\u53cb","year":"2009","journal-title":"Journal of Military Surgeon in Southwest China"},{"issue":"20","key":"10.1002\/14651858.CD006627.pub2-BIB0327|cit327","first-page":"71","article-title":"Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia","volume":"18","author":"\u80e1\u534e\u5ef7","year":"2011","journal-title":"\u4e2d\u56fd\u5f53\u4ee3\u533b\u836f"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0328|cit328","first-page":"43","article-title":"Ziprasidone treatment of low dose clozapine in refractory schizophrenia 33 patients","volume":"15","author":"\u83ab\u4e9a\u8389","year":"2010","journal-title":"Zhejiang Practical Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0329|cit329","first-page":"1275, 1380","article-title":"Ziprasidone and quetiapine treatment episode schizophrenia\u00a0","volume":"20","author":"\u8463\u4f1f","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0330|cit330","first-page":"77","article-title":"Ziprasidone and risperidone in the treatment of female patients with schizophrenia control study","volume":"2","author":"\u8463\u4f1f","year":"2010","journal-title":"Modern Diagnosis and Treatment"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0331|cit331","first-page":"1061","article-title":"Ziprasidone in the treatment of first diagnosis of schizophrenia","volume":"19","author":"\u8463\u592a\u65b0","year":"2007","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0332|cit332","first-page":"363","article-title":"Ziprasidone and risperidone on treatment of schizophrenia","volume":"12","author":"\u8521\u8fdb\u4f1f","year":"2009","journal-title":"China Pharmacist"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0333|cit333","first-page":"190","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia\u00a0","volume":"3","author":"\u8983\u677e","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0334|cit334","first-page":"123","article-title":"Ziprasidone, and risperidone in the treatment of adolescent schizophrenia-control study","volume":"6","author":"\u8bb8\u4e9a\u5e73","year":"2010","journal-title":"\u4e9a\u592a\u4f20\u7edf\u533b\u836f"},{"issue":"23","key":"10.1002\/14651858.CD006627.pub2-BIB0335|cit335","first-page":"2788, 2793","article-title":"Ziprasidone and clozapine treatment of schizophrenia","volume":"20","author":"\u8bb8\u5fd7\u5e73","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0336|cit336","first-page":"137","article-title":"The comparative investigation between ziprasidone and risperidone in the treatment of schizophrenia in children","volume":"36","author":"\u8c22\u709c\u9e9f","year":"2009","journal-title":"\u56fd\u9645\u7cbe\u795e\u75c5\u5b66\u6742\u5fd7"},{"issue":"11","key":"10.1002\/14651858.CD006627.pub2-BIB0337|cit337","first-page":"1380","article-title":"Ziprasidone treatment of schizophrenia clinical analysis of 65 cases","volume":"22","author":"\u8c22\u80b2\u5357","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0338|cit338","first-page":"3715","article-title":"Controlled study of ziprasidone and risperidone in the treatment of schizophrenia","volume":"12","author":"\u8d75\u656c\u5e73","year":"2010","journal-title":"\u533b\u5b66\u4fe1\u606f(\u4e2d\u65ec\u520a)"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0339|cit339","first-page":"559","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"22","author":"\u8d75\u660e\u4e3d","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"24","key":"10.1002\/14651858.CD006627.pub2-BIB0340|cit340","first-page":"72","article-title":"Ziprasidone and risperidone in the treatment of schizophrenia","volume":"30","author":"\u8d75\u9752\u971e","year":"2009","journal-title":"Journal of Medical Forum [\u533b\u836f\u8bba\u575b\u6742\u5fd7]"},{"issue":"07","key":"10.1002\/14651858.CD006627.pub2-BIB0341|cit341","first-page":"4219","article-title":"Ziprasidone and aripiprazole improve control study of first episode schizophrenia and social functions","volume":"24","author":"\u9093\u5e7f","year":"2011","journal-title":"\u533b\u5b66\u4fe1\u606f(\u4e0a\u65ec\u520a)"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0342|cit342","first-page":"929","article-title":"Ziprasidone and aripiprazole treatment of first episode of schizophrenia","volume":"15","author":"\u90a2\u9999\u7136","year":"2011","journal-title":"\u57fa\u5c42\u533b\u5b66\u8bba\u575b"},{"issue":"20","key":"10.1002\/14651858.CD006627.pub2-BIB0343|cit343","first-page":"3110","article-title":"Ziprasidone and risperidone in the treatment of female schizophrenia","volume":"17","author":"\u90d1\u5b66\u5b9d","year":"2008","journal-title":"Modern Research of Integrated Chinese and Western Medicine [\u73b0\u4ee3\u4e2d\u897f\u533b\u7ed3\u5408\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0344|cit344","first-page":"46","article-title":"Ziprasidone risperdal in the treatment of schizophrenia\u00a0","volume":"8","author":"\u90d1\u5e86\u6885","year":"2008","journal-title":"\u4e2d\u5916\u533b\u7597"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0345|cit345","first-page":"434","article-title":"Ziprasidone and olanzapine in schizophrenia","volume":"27","author":"\u949f\u5c0f\u5175","year":"2009","journal-title":"Journal of the Guangdong Medical College"},{"issue":"05","key":"10.1002\/14651858.CD006627.pub2-BIB0346|cit346","first-page":"11","article-title":"Ziprasidone treatment of female patients with schizophrenia, efficacy and quality of life impact study","volume":"41","author":"\u963f\u6000\u7ea2","year":"2011","journal-title":"\u9752\u6d77\u533b\u836f\u6742\u5fd7"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0347|cit347","first-page":"577","article-title":"Ziprasidone and quetiapine treatment 30 patients in each episode schizophrenia","volume":"4","author":"\u9646\u7231\u76ca","year":"2009","journal-title":"\u5185\u79d1"},{"issue":"15","key":"10.1002\/14651858.CD006627.pub2-BIB0348|cit348","first-page":"10","article-title":"Ziprasidone Efficacy of first-episode schizophrenia treatment","volume":"8","author":"\u9648\u6069\u6c11","year":"2010","journal-title":"\u793e\u533a\u533b\u5b66\u6742\u5fd7"},{"issue":"18","key":"10.1002\/14651858.CD006627.pub2-BIB0349|cit349","first-page":"111","article-title":"Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia","volume":"9","author":"\u9648\u6167","year":"2011","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0350|cit350","first-page":"38","article-title":"Ziprasidone substitution of female patients with schizophrenia. Risperidone study of the Effect of prolactin","volume":"42","author":"\u9648\u6625\u6885","year":"2010","journal-title":"Nei Moivgol Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD006627.pub2-BIB0351|cit351","first-page":"1273, 1301","article-title":"Control study of ziprasidone and risperidone in the treatment of schizophrenia","volume":"20","author":"\u96f7\u5e86\u534e","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"24","key":"10.1002\/14651858.CD006627.pub2-BIB0352|cit352","first-page":"56","article-title":"Clozapine with ziprasidone capsules with a single controlled clinical study the treatment of schizophrenia with clozapine","volume":"9","author":"\u989c\u5efa\u8f89","year":"2011","journal-title":"\u4e2d\u5916\u533b\u5b66\u7814\u7a76"},{"issue":"3","key":"10.1002\/14651858.CD006627.pub2-BIB0353|cit353","first-page":"163","article-title":"The comparation of effects and security of ziprasidone and quetiapine in the treatment of schizophrenia","volume":"31","author":"\u9a6c\u5146\u5cf0","year":"2009","journal-title":"\u5c71\u4e1c\u533b\u5b66\u9ad8\u7b49\u4e13\u79d1\u5b66\u6821\u5b66\u62a5"},{"issue":"15","key":"10.1002\/14651858.CD006627.pub2-BIB0354|cit354","first-page":"1748","article-title":"Ziprasidone efficacy of cognitive function in patients with chronic schizophrenia\u00a0","volume":"20","author":"\u9ad8\u661f\u6d77","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"10","key":"10.1002\/14651858.CD006627.pub2-BIB0355|cit355","first-page":"1214","article-title":"Ziprasidone and risperidone in the treatment of elderly clinical controlled study of schizophrenia","volume":"22","author":"\u9ec4\u5cf0","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"35","key":"10.1002\/14651858.CD006627.pub2-BIB0356|cit356","first-page":"297","article-title":"Ziprasidone and quetiapine in the treatment of elderly schizophrenia control analysis","volume":"8","author":"\u9ec4\u632f\u82f1","year":"2010","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"issue":"06","key":"10.1002\/14651858.CD006627.pub2-BIB0357|cit357","first-page":"70","article-title":"Ziprasidone, and risperidone in the treatment of schizophrenia","volume":"13","author":"\u9ec4\u667a\u8f89","year":"2011","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u533b\u836f\u6742\u5fd7"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0358|cit358","unstructured":"Mortimer A A1281014 a phase IIIb, 12 week, multi-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone versus olanzapine on quality of life in the treatment of schizophrenia and schizoaffective disorder National Research Register 2001"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0359|cit359","unstructured":"Reveley M MREC\/00\/1\/47 a phase IIIb multicentre randomised double-blind trial of ziprasidone vs olanzapine in schizophrenia National Research Register 2003"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0361|cit361","first-page":"1","volume-title":"Practice guidelines for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0363|cit363","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001945","article-title":"Ziprasidone for schizophrenia and severe mental illness","author":"Bagnall","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006627.pub2-BIB0366|cit366","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0369|cit369","first-page":"233","article-title":"The Extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal Neurological Sciences"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0370|cit370","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa Cape Town Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0373|cit373","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0375|cit375","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004578.pub3","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006627.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0378|cit378","unstructured":"Gaebel W Falkai P Weinmann S Wobrock T Treatment guidelines for schizophrenia Steinkopf 2006"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0380|cit380","doi-asserted-by":"crossref","unstructured":"Guy 1976 ECDEU assessment for psychopharmacology. National Institute of Mental Health 1976","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0383|cit383","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration 2008","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0386|cit386","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0387|cit387","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/schbul\/sbn087","article-title":"Haloperidol versus chlorpromazine for treatment of schizophrenia","volume":"34","author":"Leucht","year":"2008","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Liebermann","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0395|cit395","first-page":"329","article-title":"New assessment of atypical antipsychotics","volume":"71","author":"M\u00f6ller","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0397|cit397","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \"Just the Facts\" What we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006627.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0402|cit402","unstructured":"WHO New understanding, new hope The world health report 2001-Mental Health 2001"},{"key":"10.1002\/14651858.CD006627.pub2-BIB0403|cit403","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H Pinfold V Takriti Y The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007 2007"},{"issue":"2","key":"10.1002\/14651858.CD006627.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006627.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:58:05Z","timestamp":1748325485000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006627.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":404,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006627.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}